Cytokinetics announced Late Breaking Science presentations on MAPLE-HCM at upcoming cardiology conferences in New Orleans.
Quiver AI Summary
Cytokinetics, Incorporated announced that it will present three Late Breaking Science presentations related to its MAPLE-HCM trial at both the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions, taking place in New Orleans from November 7-10, 2025. Key presentations will include findings on the effects of aficamten versus metoprolol on patient-reported health and long-term outcomes in obstructive hypertrophic cardiomyopathy. The company is advancing aficamten, an investigational cardiac myosin inhibitor, following positive Phase 3 trial results and is also developing several other investigational drugs aimed at treating cardiac muscle dysfunction.
Potential Positives
- Announcement of significant presentations at major medical conferences, highlighting Cytokinetics' commitment to advancing research in hypertrophic cardiomyopathy.
- Positive clinical trial results for aficamten, enhancing potential for regulatory approvals and commercialization in the near future.
- Engagement with leading medical professionals and institutions at the upcoming presentations, which can strengthen collaborations and increase visibility in the medical community.
- Highlighting multiple investigational products in the pipeline, demonstrating Cytokinetics' dedication to innovation in cardiovascular therapies.
Potential Negatives
- Press release largely focuses on positive developments and upcoming presentations, which may indicate a lack of immediate results or approvals from regulatory bodies.
- Reiteration of that the drug candidates are still investigational and not yet approved may undermine investor confidence in the company's current pipeline and future potential.
- Multiple risks and uncertainties related to drug development, testing, and regulatory approvals are highlighted, which could deter investors and partners.
FAQ
What is the focus of the MAPLE-HCM study?
The MAPLE-HCM study compares Metoprolol and Aficamten in patients with LVOT obstruction and exercise capacity issues in HCM.
When are Cytokinetics' presentations scheduled?
Cytokinetics' presentations are on November 7-10, 2025, at the Hypertrophic Cardiomyopathy Medical Society and American Heart Association Scientific Sessions.
Who is presenting on the effects of Aficamten?
Presenters include Michael E. Nassif, Shepard D. Weiner, and Andrew Wang, highlighting various Aficamten studies in their sessions.
Where will the scientific sessions take place?
The scientific sessions will be held in New Orleans, LA, specifically during the Hypertrophic Cardiomyopathy Medical Society and AHA events.
What is Aficamten's significance in clinical trials?
Aficamten is being evaluated for its safety and efficacy in treating obstructive hypertrophic cardiomyopathy, showing promising results in trials.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 12 sales selling 60,000 shares for an estimated $2,594,950.
- EDWARD M. MD KAYE has made 0 purchases and 4 sales selling 23,844 shares for an estimated $1,228,696.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 12 sales selling 24,105 shares for an estimated $1,000,133.
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 12,661 shares for an estimated $424,227.
- WENDELL WIERENGA sold 4,375 shares for an estimated $256,725
- ROBERT ARTHUR HARRINGTON sold 2,150 shares for an estimated $104,640
- MUNA BHANJI sold 1,454 shares for an estimated $43,227
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 172 institutional investors add shares of $CYTK stock to their portfolio, and 162 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 7,647,189 shares (+76.8%) to their portfolio in Q2 2025, for an estimated $252,663,124
- MARSHALL WACE, LLP removed 2,007,567 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $66,330,013
- POINT72 ASSET MANAGEMENT, L.P. removed 1,722,984 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,927,391
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,310,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,293,501
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,256,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,517,403
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,160,315 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,336,807
- JANUS HENDERSON GROUP PLC removed 1,007,582 shares (-95.3%) from their portfolio in Q2 2025, for an estimated $33,290,509
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CYTK Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
- Needham issued a "Buy" rating on 09/02/2025
- Citigroup issued a "Buy" rating on 09/02/2025
- Stifel issued a "Buy" rating on 09/02/2025
- JMP Securities issued a "Market Outperform" rating on 09/02/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 12 analysts offer price targets for $CYTK in the last 6 months, with a median target of $80.0.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $82.0 on 10/06/2025
- Jason Zemansky from B of A Securities set a target price of $56.0 on 10/02/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $120.0 on 09/29/2025
- Mayank Mamtani from B. Riley Securities set a target price of $80.0 on 09/22/2025
- Cory Kasimov from Evercore ISI Group set a target price of $80.0 on 09/03/2025
- David Lebowitz from Citigroup set a target price of $84.0 on 09/02/2025
- Serge Belanger from Needham set a target price of $72.0 on 09/02/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM ), at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 7, 2025, and at the American Heart Association Scientific Sessions 2025 taking place November 7-10, 2025, both in New Orleans, LA.
Hypertrophic Cardiomyopathy Medical Society Scientific Sessions
Late Breaking Science Presentation
Title:
Effect of
Aficamten
vs
Metoprolol
on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy
Presenter:
Michael E. Nassif, M.D., University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute
Date:
November 7, 2025
Session Title:
Featured Science: Hypertrophic Cardiomyopathy Medical Society
Session Time:
6:00 PM – 6:35 PM CT
Presentation Time:
6:16 PM – 6:22 PM CT
Location:
R01
Oral Presentation
Title:
Long-term Impact of
Aficamten
on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM
Presenter:
Shepard D. Weiner, M.D., Columbia University Irving Medical Center
Date:
November 7, 2025
Session Title:
Hypertrophic Cardiomyopathy Medical Society Oral Abstracts
Session Time:
2:40 PM – 3:30 PM CT
Presentation Time:
2:50 PM – 2:58 PM CT
Location:
R02-R03
Poster Presentation
Title:
Outcomes Following Septal Myectomy in Young Patients with Obstructive Hypertrophic Cardiomyopathy
Presenter:
Daniel Kamna, D.O., Oregon Health & Science University
Date:
November 7, 2025
Session Title:
Hypertrophic Cardiomyopathy Medical Society Posters
Session Time:
6:30 PM – 7:30 PM CT
Location:
R04-R05 Posters
American Heart Association Scientific Sessions 2025
Late Breaking Science Presentations
Title:
Clinical Responses to
Aficamten
Monotherapy Compared with
Metoprolol
Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis
Presenter:
Andrew Wang, M.D., Duke University Medical Center
Date:
November 8, 2025
Session Title:
From Madrid to Mardi Gras: Heart Failure Trials on Parade
Session Time:
1:30 PM – 2:45 PM CT
Presentation Time:
1:59 PM – 2:07 PM CT
Location:
211-213
Title:
Effect of
Aficamten
versus
Metoprolol
Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial
Presenter:
Neal K. Lakdawala, M.D., Brigham and Women’s Hospital, Harvard Medical School
Date:
November 9, 2025
Session Title:
Biological and Pragmatic Interventions in Heart Failure: From Present to Future
Session Time:
8:00 AM – 9:15 AM CT
Presentation Time:
8:24 AM – 8:32 AM CT
Location:
211-213
Moderated Poster Presentations
Title:
Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
Presenter:
Henri Lu, M.D., Brigham and Women’s Hospital, Harvard Medical School
Date:
November 8, 2025
Session Title:
Beyond the Usual Suspects: Imaging Insights in HCM and Rare Cardiomyopathies
Session Time:
9:15 AM – 10:30 AM CT
Poster Presentation Time:
9:43 AM – 9:48 AM CT
Location:
Clinical Science Zone 1, Moderated Digital Poster 7
Title:
Aficamten
is Safe and Effective in oHCM with Comorbidities Obesity, Hypertension, and Diabetes: a SEQUOIA-HCM Sub-study
Presenter:
Matthew M. Y. Lee, Ph.D., MBChB, School of Cardiovascular and Metabolic Health, University of Glasgow
Date:
November 8, 2025
Session Title:
Targeting the Thickened Heart: Advances in Hypertrophic Cardiomyopathy Therapy
Session Time:
10:45 AM – 11:55 AM CT
Poster Presentation Time:
11:13 AM – 11:18 AM CT
Location:
Clinical Science Zone 2, Moderated Digital Poster 24
Title:
Effect of
Aficamten
in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy
Presenter:
Xiaowen Wang, M.D., MPH, Brigham and Women’s Hospital, Harvard Medical School
Date:
November 8, 2025
Session Title:
Heart Failure and Cardiomyopathy: From Bench to Bedside
Session Time:
3:15 PM – 4:25 PM CT
Poster Presentation Time:
4:04 PM – 4:09 PM CT
Location:
Clinical Science Zone 2, Moderated Digital Poster 22
Title:
Chronic
Aficamten
Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM Trial
Presenter:
Sheila M. Hegde, M.D., MPH, UT Southwestern Medical Center and Brigham and Women’s Hospital, Harvard Medical School
Date:
November 8, 2025
Session Title:
Imaging Insights from Multicenter Clinical Trials
Session Time:
10:45 AM – 11:55 AM CT
Poster Presentation Time:
10:45 AM – 10:50 AM CT
Location:
Clinical Science Zone 1, Moderated Digital Poster 8
Title:
Lactate Dehydrogenase and Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial
Presenter:
Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of Glasgow
Date:
November 9, 2025
Session Title:
Drivers of Heart Failure: Environmental and Behavioral Factors
Session Time:
9:15 AM – 10:30 AM CT
Poster Presentation Time:
10:04 AM – 10:09 AM CT
Location:
Clinical Science Zone 2, Moderated Digital Poster 18
Poster Presentations
Title:
Semiquantitative Urine Dipstick Protein Assessments Predict Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial
Presenter:
Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of Glasgow
Date:
November 8, 2025
Session Title:
Biomarkers in HF: Past, Present, and Future
Session Time:
2:30 PM – 3:30 PM CT
Location:
Clinical Science Zone 2
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, an investigational cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten , a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .
Disclaimer
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
